Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $6.8 million.

  • Orchestra BioMed Holdings' Accumulated Expenses fell 280.07% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 280.07%. This contributed to the annual value of $6.1 million for FY2024, which is 1815.89% up from last year.
  • As of Q3 2025, Orchestra BioMed Holdings' Accumulated Expenses stood at $6.8 million, which was down 280.07% from $6.6 million recorded in Q2 2025.
  • Over the past 5 years, Orchestra BioMed Holdings' Accumulated Expenses peaked at $7.0 million during Q3 2024, and registered a low of $202931.0 during Q1 2022.
  • In the last 4 years, Orchestra BioMed Holdings' Accumulated Expenses had a median value of $4.3 million in 2023 and averaged $4.3 million.
  • Over the last 5 years, Orchestra BioMed Holdings' Accumulated Expenses had its largest YoY gain of 150448.63% in 2023, and its largest YoY loss of 422.25% in 2023.
  • Over the past 4 years, Orchestra BioMed Holdings' Accumulated Expenses (Quarter) stood at $5.4 million in 2022, then decreased by 4.22% to $5.1 million in 2023, then increased by 18.16% to $6.1 million in 2024, then increased by 12.38% to $6.8 million in 2025.
  • Its last three reported values are $6.8 million in Q3 2025, $6.6 million for Q2 2025, and $5.4 million during Q1 2025.